Stock Track | Hims & Hers Health Plunges 7.35% in After-Hours Trading on Mixed Q4 Earnings, Weak Guidance and Regulatory Concerns

Stock Track

Feb 24

Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.

The drop is primarily attributed to the company's mixed fourth-quarter 2025 financial results. While earnings per share beat analyst estimates, revenue of $617.8 million slightly missed expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.

Adding to investor concerns, a regulatory filing highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. This regulatory overhang, combined with a noted decline in gross margin, contributed to the after-hours sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136201540"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136201540\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136201540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136201540","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plunges 7.35% in After-Hours Trading on Mixed Q4 Earnings, Weak Guidance and Regulatory Concerns","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.</p><p>The drop is primarily attributed to the company's mixed fourth-quarter 2025 financial results. While earnings per share beat analyst estimates, revenue of $617.8 million slightly missed expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.</p><p>Adding to investor concerns, a regulatory filing highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. This regulatory overhang, combined with a noted decline in gross margin, contributed to the after-hours sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plunges 7.35% in After-Hours Trading on Mixed Q4 Earnings, Weak Guidance and Regulatory Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plunges 7.35% in After-Hours Trading on Mixed Q4 Earnings, Weak Guidance and Regulatory Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.</p><p>The drop is primarily attributed to the company's mixed fourth-quarter 2025 financial results. While earnings per share beat analyst estimates, revenue of $617.8 million slightly missed expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.</p><p>Adding to investor concerns, a regulatory filing highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. This regulatory overhang, combined with a noted decline in gross margin, contributed to the after-hours sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1136201540","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136201540","pubTimestamp":1771895022,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.The drop is primarily attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘后交易暴跌7.35%，因第四季度盈利好坏参半、指引疲弱和监管担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.The drop is primarily attributed to the company's mixed fourth-quarter 2025 financial results. While earnings per share beat analyst estimates, revenue of $617.8 million slightly missed expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.Adding to investor concerns, a regulatory filing highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. This regulatory overhang, combined with a noted decline in gross margin, contributed to the after-hours sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}